Floatz logo

Tenofovir Alafenamide

Hepatitis B

Sun Yat-sen UniversitySmall moleculePhase 4 / ApprovedActive
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
89/ 100

Competitive context

22 Active assets in the Hepatitis B cohort.

Asset / SponsorPhaseRating
Entecavir
Sun Yat-sen University
Phase 4BBB
Lamivudine
Fudan University
Phase 4BBB
tenofovir
Ruijin Hospital
Phase 4BB
Hepatitis B Virus Vaccine
Eunice Dube
Phase 4BB
TENOFOVIR BIS(ISOPROPYLOXYCARBONYLOXYMETHYL) ESTER
West China Hospital
Phase 4BB

View all 45 →

Same molecule, other indications

Tenofovir Alafenamide is also rated in:

HIV infectious diseaseDormant
BB
Indicative ·
71 / 100
View asset →
chronic hepatitis B virus infectionDormant
BB
Indicative ·
69 / 100
View asset →
hepatocellular carcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →